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Abstract
Introduction: Severe sepsis is associated with a high mortality rate despite implementation of guideline
recommendations. Adjunctive treatment may be efficient and require further investigation. In light of the crucial
role of immunologic derangement in severe sepsis, thymosin alpha 1 (Ta1) is considered as a promising beneficial
immunomodulatory drug. The trial is to evaluate whether Ta1 improves 28-day all-cause mortality rates and
immunofunction in patients with severe sepsis.
Methods: We performed a multicenter randomized controlled trial in six tertiary, teaching hospitals in China
between May 12, 2008 and Dec 22, 2010. Eligible patients admitted in ICU with severe sepsis were randomly
allocated by a central randomization center to the control group or Ta1 group (1:1 ratio). The primary outcome
was death from any cause and was assessed 28 days after enrollment. Secondary outcomes included dynamic
changes of Sequential Organ Failure Assessment (SOFA) and monocyte human leukocyte antigen-DR (mHLA-DR)
on day 0, 3, 7 in both groups. All analyses were done on an intention-to-treat basis.
Results: A total of 361 patients were allocated to either the control group (n = 180) or Ta1 (n = 181) group. The
mortalities from any cause within 28 days in the Ta1 group and control group were 26.0% and 35.0% respectively with
a marginal P value (nonstratified analysis, P = 0.062; log rank, P = 0.049); the relative risk of death in the Ta1 group as
compared to the control group was 0.74 (95% CI 0.54 to 1.02). Greater improvement of mHLA-DR was observed in the
Ta1 group on day 3 (mean difference in mHLA-DR changes between the two groups was 3.9%, 95% CI 0.2 to 7.6%, P =
0.037) and day 7 (mean difference in mHLA-DR changes between the two groups was 5.8%, 95% CI 1.0 to 10.5%,
P = 0.017) than in the control group. No serious drug-related adverse event was recorded.
Conclusions: The use of Ta1 therapy in combination with conventional medical therapies may be effective in
improving clinical outcomes in a targeted population of severe sepsis.
Trial registration: ClinicalTrials.gov NCT00711620.
Introduction
Severe sepsis is an important cause of admission to inten-
sive care units (ICUs) throughout the world and is char-
acterized by high mortality in adults [1-3]. Severe sepsis
is diagnosed in more than 750,000 people annually in the
United States, of whom 215,000 will die [3]. Reported
mortality rates of severe sepsis ranged from 28% to 35.5%
[3-7]. In spite of the adoption of therapeutic bundles
based on Surviving Sepsis Campaign (SSC) guidelines,
mortality is reported to be about 30% [4]. The key role of
immunologic derangement in the course and the poor
outcome has led to an increased interest in immunother-
apy [8,9]. Thymosin alpha 1 (Ta1) is a naturally occur-
ring thymic peptide first described and characterized by
Goldstein et al. [10]. It acts as an endogenous regulator
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of both the innate and adaptive immune systems [11]. It
is used worldwide for treating diseases associated with
immune dysfunction including viral infections such as
hepatitis B and C, certain cancers, and for vaccine
enhancement [12,13]. Notably, recent development in
immunomodulatory research has indicated the beneficial
effect of Ta1 treatment in septic patients. However, the
results of these studies should be viewed with caution
due to their small sample sizes and use of more than one
drug as therapeutic intervention [14-16]. This multicen-
ter randomized controlled trial was implemented to
determine the efficacy of Ta1 in treating severe sepsis.
Material and methods
We did a prospective, controlled, single-blinded, multi-
center randomized clinical trial, which was conducted in
the ICUs of six tertiary, teaching hospitals. The ethics
committee of the First Affiliated Hospital of Sun Yat-sen
University approved the protocol (200815). Written
informed consents were obtained from the patients or
next of kin for patients unable to consent. The trial was
registered with ClinicalTrials.gov, number NCT00711620.
Patients
From May 12, 2008 to Dec 22, 2010 patients diagnosed
with severe sepsis admitted to ICUs were enrolled in the
trial. The criteria for severe sepsis were a modification
of those defined by Bernard et al. (see Additional file 1)
[7]. Patients were eligible for study inclusion if they had
a known or suspected infection based on clinical data at
the time of screening and if they had two or more signs
of systemic inflammation and sepsis-induced dysfunc-
tion of at least one organ or system. Exclusion criteria
are summarized in Additional file 2.
Randomization and masking
To reduce the impact on the results from heterogeneity of
severe sepsis and inter-hospital variation in patient sources
as much as possible, stratification by investigative center in
combination with computer-generated block randomiza-
tion (block size = 8) according to the sequence of recruit-
ment was employed in the enrollment process. The
method of randomization and block size were blinded
until the data analysis was finished completely. Clinicians
who enrolled the subjects were not involved in data collec-
tion. Eligible patients were randomly assigned in a 1:1 ratio
in each hospital with four in each block assigned to receive
the study drug and the other four to the control group
after telephone verification through a randomization cen-
ter. The allocation sequence was concealed from the
researchers. To prevent advance knowledge of treatment
assignment and subversion of the allocation sequence, trial
entry sheet of the case report form (CRF) was filled out
and informed consent was obtained before disclosing the
unique participant number and the allocated group; the
unique number generated could not be changed and
deleted afterward. We used normal saline as placebo.
Patients were blinded to the treatment assignments. All
statistical analysis was done with masking maintained.
Study drug administration and sepsis management
In the Ta1 group, patients received subcutaneous injec-
tions of 1.6 mg Ta1 (ZADAXIN™, SciClone Pharmaceu-
ticals, Foster City, CA, USA) twice per day for five
consecutive days, then once per day for two consecutive
days. Prior to administration, the lyophilized powder is to
be reconstituted with 1 ml of the provided diluent (sterile
water for injection). After reconstitution, the final concen-
tration of Ta1 is 1.6 mg/ml. In the control group, patients
received subcutaneous injections of 1 mL normal saline
twice per day for five consecutive days, then once per day
for two consecutive days. According to trial protocol, ther-
apy had to be started within 4 hrs after enrollment.
The treating physicians dictated patient care to current
international guidelines [17], including adequate empiric
antibiotic therapy based on current recommendations,
ventilation regimen (pressure control mode), blood glu-
cose control, resuscitation and hemodynamic support,
organ support, sedation or analgesia as needed and ade-
quate nutrition. Empirical antibiotic therapy was consid-
ered adequate when at least one effective drug was
included in the empirical antibiotic treatment within the
first 24 hrs of the admission to the ICU and the optimal
dose and the correct route of administration were in
accordance with medical standards and in ICU survivors
without microbiologically detected microorganism in
bloodstream or focus. When the empirical antibiotic
therapy had to be changed after microbiological detection
of microorganism, it was considered inadequate, whereas
in non-survivors without microbiologically detected
microorganism in bloodstream or focus it was considered
not evaluable [18-20].
Outcomes and data collection
The primary efficacy end point was death from any
cause and was assessed 28 days after the initiation of
treatment assignment. Secondary outcomes included
dynamic changes of Sequential Organ Failure Assess-
ment (SOFA), CD4+/CD8+ and monocyte human leuko-
cyte antigen-DR (mHLA-DR) expression measured on
day 0 (the day of enrollment), 3 and 7 in both groups.
All mHLA-DR measurements were done in the center
laboratory of the First Affiliated Hospital of Sun Yat-sen
University. 1 ml unprocessed EDTA whole blood was
stored on ice at once after drawing and was transferred
to the center laboratory as soon as possible to guarantee
measurement within 3 hrs after blood drawing. The
method of measuring mHLA-DR was mentioned in our
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previous paper [21]. Once patients were enrolled, data
including demographic characteristics, microbiological
findings (primary infection source and the identified
microorganisms) and comorbidities were collected when
available. The following clinical parameters were
recorded on specific days after enrollment: on day 0, the
severity as assessed by the Acute Physiology and
Chronic Health Evaluation II (APACHE II); on day 0, 3,
7, SOFA, hematologic and biochemical findings, results
of mHLA-DR, CD4+/CD8+ tests. The time of the first
organ dysfunction was retrospectively estimated accord-
ing to objective data such as blood gas analysis when
the patient was enrolled.
Statistical analysis and sample size
Based on a previous study [22], a sample size of 334
patients was required to show a reduction in 28-day
mortality rate from 50% to 35% by Ta1 treatment, with
a two-sided test (a error = 5%; power = 80%). Consider-
ing a possible drop-out rate of 10%, the trial would need
to enroll 368 patients in total. Demographic data, out-
come data and other laboratory parameters were sum-
marized by frequency for categorical variables and mean
± standard deviation (SD) or median with interquartile
range (IQR) for continuous variables. Proportions were
compared with chi-square test or Fisher’s exact test.
Continuous variables were tested by means of t test
with normal distribution or Wilcoxon rank-sum test
with non-normal distribution. The comparison of pri-
mary outcome between two groups was performed by
means of Cochran-Mantel-Haenszel test, in which
patients were stratified on a number of baseline covari-
ates such as mHLA-DR, scores of APACHE and SOFA,
surgical and cancer history, sex and age. The corre-
sponding relative risks (RRs) with 95% confidence inter-
vals (CIs) were computed with logit-adjusted method.
Kaplan-Meier estimates without adjustment for baseline
covariates were used for survival time analysis, and log-
rank tests for comparison. To estimate mean changes
from baseline in laboratory parameters, linear mixed
models for repeated measures were employed, taking
into account the clustering of participating centers and
repeated measurements within patients. This model
included terms for baseline measurement, treatment
group, visit, and treatment × visit interaction. Least-
squares means with 95% CIs were reported. We also
analyzed the efficacy parameters of the study drug in
different prespecified subgroups. The heterogeneity of
treatment effects among subgroups was assessed with
use of interaction tests. Consistent with the intention-
to-treat principle, all analyses were based on all available
population, consisting of those with a baseline and at
least one post-baseline efficacy measurement, neither
making any assumption nor imputing the missing data.
All statistical analyses were done with the SAS software
(SAS 9.1.3; SAS Institute Inc., Cary, NC, USA). Two-
sided P values were reported and a P value less than
0.05 was considered as statistically significant.
Results
Study profile
Between May 12, 2008 and Dec 22, 2010, 367 eligible
patients were randomized (Figure 1). In the Ta1 group,
two patients were excluded: one patient withdrew the con-
sent after being diagnosed with typhus and was transferred
to the infectious disease hospital immediately; in the other
case, consent was withdrawn before the infusion. In the
control group, consents were withdrawn after the enroll-
ment in four cases. A total of 361 randomized patients
were followed up for the entire 28-day study period with-
out drop-out. Of 181 patients in Ta1 group, 162 patients
completed the trial in adherence with the protocol regard-
ing the use of drugs, while the other 19 patients received
at least 1.6 mg Ta1 but their treatments did not fully
adhere to the protocol because they were transferred out
of ICU.
Baseline data
Both groups had similar characteristics in most demo-
graphic and baseline variables (Table 1), although patients
in the Ta1 group had a longer period between the time of
first organ dysfunction observed and the time of enroll-
ment (42 hrs vs. 28 hrs, P = 0.003). Nearly 80% of the
patients had at least two dysfunctional organs at the time
of enrollment. The pulmonary and cardiovascular systems
were the most commonly affected organ systems with an
incidence of 94.7% and 65.7% respectively. The most com-
mon sites of infection were lung and abdomen, with an
incidence of 74.5 and 27.4%, with mixed pathogens or
gram-negative organisms accounting for the majority
of cases. There was no difference in adequate antibiotic
treatment (refer to Table 2). Baseline laboratory data
were comparable between the two groups and shown in
Table 3. Patients in the Ta1 group had a lower level of
mHLA-DR (47.1 vs. 58.0% in the control group, P = 0.02),




Within 28 days after the enrollment, 47 of 181 patients in
the Ta1 group (26.0%) and 63 of 180 patients in the con-
trol group (35.0%) expired. The relative risk of death in
the Ta1 group as compared to the control group was 0.74
(95% CI 0.54 to 1.02) with a P value of 0.062 in the non-
stratified analysis. There was a 9.0% (95% CI -0.5 to 18.5%)
absolute reduction in mortality in the Ta1 group. Survival
time-to-event curves of the two groups are presented in
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Figure 2. Patients in the Ta1 group survived longer after
enrollment than the control group (log rank, P = 0.049). A
total of 52 of 181 patients in the Ta1 group (28.7%) and
71 of 180 patients in the control group (39.4%) died in
hospital. The relative risk of death in hospital in the Ta1
group was 0.73 (95% CI 0.54 to 0.98) compared to the
control group with a P value of 0.032. There was no signif-
icant difference in ICU mortality, ventilation-free days,
ICU-free days, the length of ICU stay and duration of
mechanical ventilation between the two groups (Table 4).
Secondary outcomes
Dynamic changes in SOFA and laboratory measurements
are summarized in Table 5. A sustained increase in
mHLA-DR values (% of positive monocytes) was observed
in both groups. The mean changes from baseline on day 3
and day 7 were 4.1% and 11.2% in the control group, and
8.0% and 17.0% in the Ta1 group. Patients in the Ta1
group had lower baseline mHLA-DR than those in the
control group on day 0. The average mHLA-DR became
comparable with no statistically significant difference
between the two groups on day 3 and 7. Greater improve-
ments in mHLA-DR were observed in patients in the Ta1
group on day 3 (mean difference in mHLA-DR changes
between the two groups was 3.9%, 95% CI 0.2 to 7.6%, P =
0.037) and day 7 (mean difference in mHLA-DR changes
between two groups was 5.8%, 95% CI 1.0 to 10.5%, P =
0.017). The average SOFA score changes on day 3 and day
7 were -1.3 (95% CI -1.7 to -0.8, P < 0.001) and -1.8 (95%
CI -2.4 to -1.3, P < 0.001) in the control group, and -1.8
(95% CI -2.3 to -1.4, P < 0.001) and -2.5 (95% CI -3.1 to
-2.0, P < 0.001) in the Ta1 group. The decreasing ten-
dency within 7 days in SOFA score seemed to favor the
Assessed for eligibility (n=535) 
Excluded (n=168) 
i   Not meeting inclusion criteria (n= 98) 
i   Declined to participate (n=13) 
i   Other reasons (incomplete data to assess 
inclusions or exclusions ) (n=57) 
Randomized (n= 367) 
Allocated to intervention (n=183) 
iTα1 + conventional therapy (n=181) 
i1 consent withdrawn,1 no longer met criteria  
0 Lost to follow-up 0 Lost to follow-up. 162 (89.5%) finished study 
and completed planned Tα1 therapy; 19 
finished study but did not complete all the 
planned Tα1 therapy 
Analyzed (n=181) Analyzed (n=180) 
Allocated to control (n=184) 
i  conventional therapy (n=180) 
i4 consents withdrawn   
Figure 1 Study profile. Ta1, thymosin alpha 1.
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Table 1 Baseline characteristics in both study groups.
Control group Ta1 group P value
n 180 181
Age (yr) 66.4 ± 12.6 64.7 ± 14.5 0.46
Age group 0.79
< 50 yr 21 (11.7%) 24 (13.3%)
50-60 yr 39 (21.7%) 45 (24.9%)
61-70 yr 39 (21.7%) 39 (21.6%)
71-yr 81 (45.0%) 73 (40.3%)
Male 131 (72.8%) 141 (77.9%) 0.26
Female 49 (27.2%) 40 (22.1%)
BMI 22.0 ± 3.0 22.2 ± 3.1 0.48
Prior or preexisting conditions
Congestive heart failure 8 (4.4%) 5 (2.8%) 0.39
Hypertension 79 (43.9%) 80 (44.2%) 0.95
Coronary heart disease 19 (10.6%) 22 (12.2%) 0.63
Liver disease 10 (5.6%) 9 (5.0%) 0.80
COPD 28 (15.6%) 29 (16.0%) 0.90
Nervous system diseases 33 (18.3%) 32 (17.7%) 0.87
Diabetes 34 (18.9%) 40 (22.1%) 0.45
Recent trauma 8 (4.4%) 8 (4.4%) 0.99
Cancer 55 (30.6%) 60 (33.2%) 0.60
Recent surgical history 0.47
No history of surgery 103 (57.2%) 92 (50.8%)
Elective surgery 41 (22.8%) 46 (25.4%)
Emergency surgery 36 (20.0%) 43 (23.8%)
Other indicators of disease severity
Mechanical ventilation 143 (79.4%) 146 (80.7%) 0.77
Shock 74 (41.1%) 64(35.4%) 0.26
Use of any vasopressor or dobutamine 72 (40.0%) 71(39.2%) 0.88
Low-dose corticoid 18 (10.0%) 20 (11.1%) 0.75
Blood transfusion 54 (30.0%) 64 (35.4%) 0.28
Baseline acute organ dysfunctions
Pulmonary 170 (94.4%) 172 (95.0%) 0.80
Renal 48 (26.7%) 53 (29.3%) 0.58
Cardiovascular 113 (62.8%) 124 (68.5%) 0.25
Hematologic 69 (38.3%) 67 (37.0%) 0.80
Hepatic 39 (21.7%) 27 (14.9%) 0.10
Number of acute organ dysfunction 0.97
1 32 (17.8%) 29 (16.0%)
2 75 (41.7%) 77 (42.5%)
3 45 (25.0%) 48 (26.5%)
4 18 (10.0%) 19 (10.5%)
5 10 (5.6%) 8 (4.4%)
APACHE II score 21.6 ± 7.7 22.3 ± 6.7 0.35
SOFA score 7.7 ± 3.9 7.9 ± 3.6 0.65
Respiratory system 2.6 ± 1.0 2.7 ± 0.9 0.22
Coagulation 0.8 ± 1.1 1.0 ± 1.2 0.17
Cardiovascular system 1.4 ± 1.6 1.2 ± 1.5 0.40
Liver 0.6 ± 0.9 0.5 ± 0.8 0.38
Nervous system 1.3 ± 1.4 1.4 ± 1.4 0.69
Renal system 1.0 ± 1.3 1.0 ± 1.4 0.85
Time from first organ dysfunction to enrollment (hr) median(IQR) 28.0 (15.0-48.0) 42.0 (24.0-72.0) 0.003
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range;
SOFA, Sequential Organ Failure Assessment; Ta1, thymosin alpha 1; yr, year.
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Ta1 group but with no significant difference in changes
between the two groups. The ratio of CD4+/CD8+
remained unchanged during the 7 days in both groups.
Subgroup analysis
Mortality rates among prespecified subgroups of patients
are shown in Figure 3. Prespecified analyses of the primary
end point, where patients were stratified according to
APACHE II score, SOFA score, mHLA-DR level, history
of surgery or cancer, sex and age, showed that Ta1 tended
to improve outcome but without statistical significance. In
a subgroup analysis of patients with cancer, the relative
risk of death of the Ta1 group when compared to the con-
trol group was 0.46 (95% CI 0.25 to 0.86, P = 0.01); on the
other hand, in non-cancerous patients, the relative risk of
death of the Ta1 group was 0.91 (P = 0.07 by the test of
interaction).
Adverse events
Safety and tolerability assessment of Ta1 (see Additional
file 3) was based on the comparison of all available
information obtained from the two groups with respect
to detected outliers in laboratory safety data, drug-
related serious adverse events (assessed by the investiga-
tor) and deterioration of organ and system function
(assessed by the individual SOFA component scoring for
respiratory, cardiovascular, hepatic, coagulation, renal
and nervous systems that arose during the treatment).
In this study, no Ta1-related severe adverse event
(SAE) was reported and no treatment was discontinued
due to intolerance or adverse events. There were no sta-
tistically significant differences between the control and
Ta1 group with regard to the frequency of outlying
laboratory values and all-cause organ or system impair-
ment (refer to Table 6).
Discussion
Immune system dysregulation plays a significant role in
the course of sepsis. Previously, it was believed that the
exaggerated pro-inflammatory response and its associated
Table 2 Sites, causes of infection and adequate antibiotic










Lung 133 (73.9%) 136
(75.1%)
0.79
Abdomen 48 (26.7%) 51 (28.2%) 0.75
Urinary tract 5 (2.8%) 2 (1.1%) 0.28
Positive blood culture 10 (5.6%) 11 (6.1%) 0.83
Other† 18 (10.0%) 16 (8.8%) 0.71
Results of pathogens 0.99
Pure gram-negative 47 (26.1%) 51 (28.2%)
Pure gram-positive 15 (8.3%) 14 (7.7%)
Pure fungus 22 (12.2%) 21 (11.6%)
Mixed 57 (31.7%) 56 (30.9%)
Culture negative 39 (21.7%) 39 (21.6%)
Types of organisms‡
Gram-positive
Staphylococcus aureus 7 (3.9%) 9 (5.0%) 0.62
Other staphylococcus
species
9 (5.0%) 12 (6.6%) 0.51
Enterococcus species 22 (12.2%) 23 (12.7%) 0.89
Other gram-positive 18 (10.0%) 14 (7.7%) 0.45
Gram-negative
Klebsiella species 18 (10.0%) 22 (12.2%) 0.51
Escherichia coli 25 (13.9%) 23 (12.7%) 0.74
Pseudomonas species 32 (17.8%) 32 (17.7%) 0.98
Acinetobacter 8 (4.4%) 15 (8.3%) 0.14
Enterobacter species 4 (2.2%) 4 (2.2%) 1.00
Other gram-negative 14 (7.8%) 16 (8.8%) 0.71
Fungus
Candida albicans 43 (23.9%) 38 (21.0%) 0.51
Other candida species 20 (11.1%) 15 (8.3%) 0.36
Mould 1 (0.6%) 4 (2.2%) 0.37
Other fungus 6 (3.3%) 6 (3.3%) 0.99
Empirical antibiotic therapy 0.903
Adequate 136 (75.6%) 133
(73.5%)
Inadequate 34 (18.9%) 37 (20.4%)
Not evaluable 10 (5.6%) 11 (6.1%)
*Patients may have had more than one site of infection; †other sites of
infection included skin, central nervous system, bones and joints; ‡patients
may have had more than one organism cultured. Ta1, thymosin alpha 1.
Table 3 Baseline levels of laboratory values.
Control group Ta1 group P value
mHLA-DR (%)
Median (IQR) 58.0 (33.9-83.0) 47.1 (26.4-71.1) 0.02
mHLA-DR group 0.16
< 30% (n, %) 36 (20.3%) 50 (27.6%)
≥ 30- < 45% (n, %) 29 (16.4%) 32 (17.7%)
≥ 45- < 85% (n, %) 70 (39.6%) 71 (39.2%)
≥ 85% (n, %) 42 (23.7%) 28 (15.5%)
CD4+/CD8+
Median (IQR) 1.95 (1.18-3.30) 1.87 (1.16-3.22) 0.64
WBC (*109)
Median level 14.3 (10.1-17.9) 14.4 (9.4-19.3) 0.78
Neutrophil (%WBC)
Median (IQR) 85.1 (80.2-90.7) 86.5 (80.8-91.0) 0.48
Lymphocyte (%WBC)
Median (IQR) 9.5 (6.0-15.3) 8.9 (5.0-14.1) 0.23
Monocyte (%)
Median (IQR) 4.80 (3.30-7.30) 4.95 (2.80-7.30) 0.66
Lactate (mmol/L)
Median (IQR) 2.1 (1.4-3.4) 2.1 (1.3-3.1) 0.86
CD, cluster of differentiation; IQR, interquartile range; mHLA-DR, monocyte
human leukocyte antigen-DR; WBC, white blood cell; Ta1, thymosin alpha 1.
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inflammation-induced organ injury were the major fac-
tors leading to deaths in sepsis. However, recent
studies indicate that heterogeneity exists in septic
patients ’ immune response, with some appearing
immunostimulated, whereas in others appearing sup-
pressed [23]. Although both pro-inflammatory and
anti-inflammatory drugs have been evaluated, few have
yet been found to significantly reduce the mortality
[24-26]. Ta1 is thought to have immunomodulating
effects primarily affecting the augmentation of T-cell func-
tion [27,28]. Ta1 has also shown actions beyond its effect
on T lymphocytes by acting as an endogenous regulator of
both the innate and adaptive immune systems [11,29].
Ta1 plays a unique role in balancing pro- and anti-inflam-
matory cytokine production through the involvement of
distinct Toll-like receptors (TLRs) acting on different den-
dritic cells (DC) subsets and involving the MyD88-depen-
dent signaling pathway. Ta1 can increase IL-12, IL-2,
IFN-a and IFN-g secretion to present antimicrobial effect
and increase IL-10 and percentage of regulatory T cells
(Tregs) to control inflammation [11,30-32]. Therefore,
theoretically, Ta1 may be an appropriate immunoregula-
tor for treating severe sepsis that is characterized by the
large heterogeneity in immune function.
Our data suggested that the administration of Ta1
reduced 28-day mortality from any cause in patients with
clinically diagnosed severe sepsis by 9.0%, with a marginal
P value (P = 0.062 in the nonstratified analysis; log rank,
P = 0.049) and decreased in-hospital mortality (P = 0.032).
Our study was prospectively set up to detect an absolute
15% mortality reduction from an expected 50% as indicated
in our previous trial and another epidemiology research
Figure 2 Kaplan-Meier estimate of the probability of 28-day survival. Ta1, thymosin alpha 1.







28-day mortality 63 (35.0%) 47 (26.0%) 0.062
In-hospital mortality 71 (39.4%) 52 (28.7%) 0.032
In-ICU mortality 48 (26.7%) 35 (19.3%) 0.098
Duration of
ventilation
Median (IQR) 6.0 (2.0-14.0) 7.0 (3.0-13.0) 0.742
ICU stay
Median (IQR) 10.5 (5.0-20.5) 11.0 (7.0-20.0) 0.254
Ventilation-free days*




Median (95% CI) 5.0 (0.3-10.7) 10.0 (6.8-15.0) 0.235
’Free days’ were calculated as the number of days that the patient was alive
and free of given measure (ventilator use and ICU stay) during the 28-day
study period. CI, confidence interval; IQR, interquartile range; Ta1, thymosin
alpha 1.
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about severe sepsis in China [22,33]. Mortality and drug
effect size were not consistent with our expectation, which
might lead to the marginal P value in the comparison of
28-day survival rate between two groups. In contrast to our
results, previous trials in adults indicated that Ta1 signifi-
cantly reduced mortality by 13.1% to 18% as compared to
the control group [14-16]. The following reasons may
explain this discrepancy in different trials. First, heteroge-
neity in patient populations and different therapeutic
approaches could have influenced the outcomes; second,
previous trials did not report the allocation concealment,
which could have an unexpected impact on results. Schulz
et al. indicated that the odds ratios were exaggerated by
41% for inadequately concealed trials and by 30% for
unclearly concealed trials [34]. Third, those studies used
more than one drug as therapeutic intervention and made
it difficult to attribute the beneficial effects observed to
each agent.
The most frequently assessed biomarker for evaluating
immune function of severe sepsis is mHLA-DR. There
seems to be a general consensus that diminished mHLA-
DR is a reliable marker for the development of immuno-
dysfuction in severe sepsis patients [35,36]. Recent studies
indicate that the dynamic change of mHLA-DR over time
was a better predictor of mortality and mHLA-DR recov-
ery was associated with a better prognosis [21,37,38]. In
the present trial, a greater improvement of mHLA-DR was
observed in the Ta1 group on day 3 and day 7 than in the
control group, which suggests that Ta1 may improve
immune function in severe sepsis. The ratio of CD4+/CD8+
is another parameter to evaluate immunological status in
sepsis. Decreased CD4+/CD8+ ratio was related to the
development of severe sepsis and multiple organ failure
(MOF) in trauma patients [39]. Some studies showed that
thymosin alpha 1 can increase CD4+/CD8+ ratio [40,41].
On the other side, one research study has indicated that
mHLA-DR, not CD4+, CD8+ or ratio of CD4+/CD8+, can
predict the prognosis of severe sepsis [42]. In our research,
we did not find statistically significant difference in the
CD4+/CD8+ ratio between the two groups. The decreasing
tendency within 7 days in SOFA score seemed to favor the
Ta1 group but with no significant difference in changes
between the two groups. However, considering the fact
that we observed the changes of these indices for only 7
days, there could have been some difference between the
two groups if the observation had been extended to 14 or
28 days.
The median time from the first organ dysfunction
detected to enrollment was more than 24 hrs in both
groups, but longer in the Ta1 group. We adopted a ret-
rospective method to determine the time window
between the onset of the first organ dysfunction detected
and study enrollment according to objective data (such
as blood gas analysis), many of which were obtained
before transferring the severe sepsis patients to the ICU
[7]. However, those patients without indicative objective
data could also have suffered from severe sepsis and the
delay in laboratory tests could substantially underesti-
mate the time after onset. In other words, the time after
onset determined by laboratory tests in non-ICU depart-
ments was out of our control and subject to errors, espe-
cially when the estimation was based on hours instead of
days. The precise time window between onset of the first
organ dysfunction and enrollment could exceed the
recorded time and could possibly be balanced between
the two groups. The better way of enrolling severe sepsis
patients in immunotherapy research may be through
mHLA-DR value, which has been proved to be a good
predictor to evaluate patients’ immune status and a good
parameter for individualized goal-directed therapy [43].
Reductions in the relative risk of death were observed
in all subgroups including those stratified according to
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Day 0 2.4 (2.0-2.9) 2.5 (2.0-2.9)
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* ΔDay 3 and ΔDay 7 were defined as the value changes on day 3 and day 7
compared with that on day 0. aP < 0.05; bP < 0.01. CD, cluster of differentiation;
CI, confidence interval; mHLA-DR, monocyte human leukocyte antigen-DR;
SOFA, Sequential Organ Failure Assessment; Ta1, thymosin alpha 1.
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age, sex, APACHE II score, SOFA score and levels of
mHLA-DR, but without statistical significance. The aim
of analyzing different prespecified subgroups in our
research was to prepare for our future research in tar-
geted specific groups of severe sepsis patients who
might benefit from the Ta1 treatment since it is unli-
kely that thymosin alpha 1 is equally beneficial to all
patients in view of the significant heterogeneity in severe
sepsis patients. The results of subgroup analysis in our
research were inconclusive and whether Ta1 is more
effective in specific groups of patients with severe sepsis
should be explored in trials with a larger sample size.
Types of pathogen and empirical antibiotic therapy are
very important factors that affect the outcome of severe
sepsis. In our study, there was no difference between
groups in these perspectives. It is noted that the origins of
microorganisms are substantially diverse in different areas
and even in different hospitals in the same area. So is
empirical therapy. In the present study, there was a high
isolation rate of gram-negative bacteria (pseudomonas,
Figure 3 Analysis of the rates and risks of death from any cause within 28 days in prespecified subgroups. APACHE, Acute Physiology
and Chronic Health Evaluation; CI, confidence interval; HLA-DR, human leukocyte antigen-DR; SOFA, Sequential Organ Failure Assessment; Ta1,
thymosin alpha 1.
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acinetobacter) compared with some other epidemiology
study of infection in ICU [44]. In fact, the relatively higher
incidence of pseudomonas and acinetobacter infections is
not unusual in China [33] so that the adequate empirical
therapy is adjusted accordingly.
Thymosin alpha 1 has been shown to be a safe and
well-tolerated agent in other studies [12,13]. Serious
adverse events were not observed in our trial. Outlying
laboratory values and all-cause organ and system impair-
ment were similar in both groups. However, subjective
sensations such as irritation or burning, general or gas-
trointestinal disorders were difficult to assess due to the
severity of disease, sedation or analgesia in severe sepsis
patients.
In our study, several factors limit the extent to which
the results can be generalized. First, the study population
was heterogeneous with respect to clinical features.
Although over 80 baseline characteristics were compar-
able between the two groups, difference in mHLA-DR
expression was present and was probably due to the het-
erogeneity in patients and the relatively small size of sam-
ples. In fact, unbalanced baseline characters between
groups were not rare in severe sepsis trials even with
large samples [45,46]. In our study, to assess whether
outcomes differed by treatment groups, linear mixed
models for longitudinal data were fit with adjustment for
the baseline value. This method has been widely used in
multicenter research [47,48]. Second, considering the
heterogeneity of severe sepsis, some patient groups could
benefit more from the intervention than other septic
patients. The future individualized and goal-directed Ta1
treatment of severe sepsis should be implemented in tar-
geted specific groups of patients. One of the biomarkers
that can be used to stratify patients according to their
immune status is mHLA-DR. Meisel et al. reported that
mHLA-DR level was associated with immunosuppression
status in sepsis patients who benefited from the granulo-
cyte-macrophage colony-stimulating factor (GM-CSF)
treatment [43]. We will try to adopt mHLA-DR target
immunosuppression patients in future study. Third, since
a considerable proportion of patients were transferred
out of ICU within one week, which makes it difficult to
guarantee that the complete laboratory and follow-up
data could be obtained, we only collected laboratory data
within 7 days and followed up the survival status for 28
days. A more extensive laboratory data collection and
extended follow-up period could possibly provide more
significant information. Fourth, there are few biomarkers
to evaluate the immunological derangement. In the pre-
sent trial, we adopted the widely used mHLA-DR. Fifth,
it is not known from our trial that whether the extension
of the treatment to more than 7 days or the increase of
dose could generate a significant improvement in the
outcomes of severe sepsis patients. Sixth, we did not
adopt the double-blind method because no identical-
appearing placebo was available and only the patients
and the statistician were blinded. To minimize the poten-
tial bias, randomization and adequate allocation conceal-
ment were meticulous in the trial [34] and the primary
and second end points were objective rather than
subjective.
Given these limitations, the present research is a preli-
minary exploration on the efficacy of thymosin alpha 1 in
severe sepsis and further double-blinded studies are
needed to explore the use of Ta1 regarding patient selec-
tion, dosage and the course of treatment.
Table 6 Frequency of patients with outlying values of laboratory safety assays and all-cause organ and system
impairment.
Control group
No. (%) (n = 180)
Ta1 group
No. (%) (n = 181)
P value
Laboratory safety assays
ALT (U/L) 43 (23.9) 38 (21.0) 0.51
AST (U/L) 44 (24.4) 43 (23.8) 0.88
Hypoglycemia 9 (5.0) 8 (4.4) 0.79
Hemoglobin (g/L) 23 (12.8) 27 (14.9) 0.56
Platelets (103/mm3) 77 (42.8) 67 (37.0) 0.26
Creatinine (mmol/L) 12 (6.7) 18 (9.9) 0.26
SOFA component scores*
Respiratory system 27 (15.0) 24 (13.3) 0.64
Coagulation system 52 (28.9) 48 (26.5) 0.62
Cardiovascular system 21 (11.7) 28 (15.5) 0.29
Hepatic system 25 (13.9) 21 (11.6) 0.51
Nervous system 22 (12.2) 14 (7.7) 0.15
Renal system 19 (10.6) 26 (14.4) 0.27
*Organ and system impairment based on the deterioration of SOFA component scores during the treatment. ALT, alanine aminotransferase; AST, aspartate
aminotransferase; SOFA, Sequential Organ Failure Assessment; Ta1, thymosin alpha 1.
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Conclusions
This RCT demonstrates that thymosin alpha 1 therapy in
combination with conventional medical therapy may be
effective in improving clinical outcomes in a targeted
population of severe sepsis. Larger multicenter studies
are indicated to confirm these findings.
Key messages
• In light of the crucial role of immunologic derangement
in severe sepsis, immunotherapy may be an important
adjunctive treatment.
• This study demonstrates that immunodulation with
thymosin alpha 1 may effectively improve outcomes of
patients with severe sepsis. A beneficial impact on the
immunofunction of patients with severe sepsis was also
observed. Further researches are needed to confirm these
findings.
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Additional file 1: Study inclusion criteria. The detailed criteria to be
fulfilled for study inclusion.
Additional file 2: Study exclusion criteria. Patients who met the
criteria were excluded.
Additional file 3: Safety and tolerability assessment of thymosin
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based on the comparison of all available information obtained from the
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drug-related serious adverse events and deterioration of organ and
system function.
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